Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2024-11-18
DOI
https://doi.org/10.3389/fphar.2024.1435639
Citations
1
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma

Tingguo Zhang, Kangshuai Li, Zongli Zhang, Yunfei Xu et al.
1 citations
Frontiers in Pharmacology
Cholangiocarcinoma and Gallbladder Cancer Studies
0.57
article

Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma

Tingguo Zhang, Kangshuai Li, Zongli Zhang, Yunfei Xu, Yi Liu
article en
1 citations

Abstract

No abstract available for this paper.
Frontiers in PharmacologyVol. 15
Qilu Hospital of Shandong University (CN)
BeiGene, Key Technology Research and Development Program of Shandong
Good health and well-being
Openalex Percentile: Top 27%
Cholangiocarcinoma and Gallbladder Cancer Studies
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.